EPHA2的丝氨酸897磷酸化参与甲状腺癌细胞中致癌性ERK1/2驱动信号的传导
在携带通过ERK1/2通路信号传导的驱动致癌基因(RET/PTC、KRAS(G12R)或BRAFV600E)的甲状腺癌细胞中,EPHA2在S897位点被强烈磷酸化。重组p90RSK可在体外磷酸化EPHA2 S897,而靶向p90RSK或ERK1/2通路其他组分的化学抑制剂可减弱S897磷酸化。RNA干扰敲低联合回补实验表明,EPHA2 S897磷酸化介导甲状腺癌细胞增殖和运动。
要点
- 在RET/PTC、KRAS(G12R)或BRAFV600E驱动的甲状腺癌细胞中,EPHA2 S897被强烈磷酸化。
- p90RSK可在体外磷酸化EPHA2 S897,ERK1/2通路抑制剂可减弱该磷酸化。
- EPHA2 S897磷酸化介导甲状腺癌细胞的增殖和运动。
核心结论
- EPHA2 S897是甲状腺癌中ERK1/2信号级联致癌活性的关键介导者。
研究设计与样本
- 研究在携带RET/PTC、KRAS(G12R)或BRAFV600E驱动致癌基因的甲状腺癌细胞中开展,采用体外磷酸化实验、化学抑制剂处理以及RNA干扰敲低联合回补实验。
主要发现
- 在携带通过ERK1/2通路信号传导的驱动致癌基因的甲状腺癌细胞中,EPHA2在S897位点被强烈磷酸化。
- 重组p90RSK可在体外磷酸化EPHA2 S897,靶向p90RSK或ERK1/2通路其他组分的化学抑制剂可减弱S897磷酸化。
- RNA干扰介导的敲低联合回补实验表明,EPHA2 S897磷酸化介导甲状腺癌细胞增殖和运动。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Phosphorylation of the intracellular domain of the EPHA2 receptor tyrosine kinase (RTK) on serine 897 (S897) has been demonstrated to mediate EPHA2 oncogenic activity. Here, we show that in thyroid cancer cells harboring driver oncogenes that signal through the extracellular regulated kinase (ERK1/2) signaling pathway [rearranged RET RTK (RET/PTC), KRAS(G12R), or BRAFV600E oncogenes], EPHA2 is robustly phosphorylated on S897. EPHA2 S897 is embedded in a consensus sequence for phosphorylation by the AGC family kinases, including p90RSK (ribosomal protein S6 kinase), a direct ERK1/2 target. Methods: We show that recombinant p90RSK phosphorylates in vitro EPHA2 S897 and that treatment with chemical inhibitors targeting p90RSK or other components of the ERK1/2 pathway blunts S897 phosphorylation. Results: RNA interference-mediated knockdown combined with rescue experiments demonstrated that EPHA2 S897 phosphorylation mediates thyroid cancer cell proliferation and motility. Conclusions: These findings point to EPHA2 S897 as a crucial mediator of the oncogenic activity of the ERK1/2 signaling cascade in thyroid cancer.
引用
- Allocca C, Cirafici AM, Laukkanen MO, et al. Serine 897 Phosphorylation of EPHA2 Is Involved in Signaling of Oncogenic ERK1/2 Drivers in Thyroid Cancer Cells. Thyroid. 2020. PMID: 32762307. doi:10.1089/thy.2019.0728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。